Cargando…
Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction
Type V-phosphodiesterase-inhibitors (PDE5i) are the first choice drugs in the treatment of erectile dysfunction (ED), being effective in 60–70% of patients. However, approximately 50% of patients per year discontinue the treatment with PDE5i after reporting poor drug efficacy or major adverse drug r...
Autores principales: | Rocca, Maria Santa, Vignoli, Alessia, Tenori, Leonardo, Ghezzi, Marco, De Rocco Ponce, Maurizio, Vatsellas, Giannis, Thanos, Dimitris, Padrini, Roberto, Foresta, Carlo, De Toni, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849189/ https://www.ncbi.nlm.nih.gov/pubmed/33536912 http://dx.doi.org/10.3389/fphar.2020.602369 |
Ejemplares similares
-
Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors
por: De Toni, Luca, et al.
Publicado: (2018) -
Estradiol–Testosterone Imbalance Is Associated with Erectile Dysfunction in Patients with Klinefelter Syndrome
por: De Rocco Ponce, Maurizio, et al.
Publicado: (2021) -
An optimized protocol for chromatin immunoprecipitation from murine inguinal white adipose tissue
por: Katsouda, Antonia, et al.
Publicado: (2023) -
Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence
por: Hatzimouratidis, Konstantinos
Publicado: (2006) -
Comparison of NGS panel and Sanger sequencing for genotyping CAG repeats in the AR gene
por: Rocca, Maria Santa, et al.
Publicado: (2020)